Compare STIM & CATX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | STIM | CATX |
|---|---|---|
| Founded | 2003 | 1983 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Medical/Dental Instruments |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 120.4M | 113.9M |
| IPO Year | 2018 | 2018 |
| Metric | STIM | CATX |
|---|---|---|
| Price | $1.26 | $0.94 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 16 |
| Target Price | $6.00 | ★ $9.43 |
| AVG Volume (30 Days) | 2.3M | ★ 4.3M |
| Earning Date | 11-04-2026 | 11-09-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 57.25 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $52,776,000.00 | N/A |
| Revenue This Year | $8.63 | N/A |
| Revenue Next Year | $9.24 | $91.56 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.80 | $0.78 |
| 52 Week High | $3.44 | $6.16 |
| Indicator | STIM | CATX |
|---|---|---|
| Relative Strength Index (RSI) | 29.12 | 28.63 |
| Support Level | $1.13 | N/A |
| Resistance Level | $1.61 | $2.40 |
| Average True Range (ATR) | 0.28 | 0.12 |
| MACD | -0.10 | 0.03 |
| Stochastic Oscillator | 4.59 | 27.35 |
Neuronetics Inc a commercial-stage medical technology company focused on designing, developing, and marketing products that improve the quality of life for patients who suffer from psychiatric disorders. Its first commercial product, the NeuroStar Advance Therapy System, is a non-invasive and non-systemic office-based treatment that uses transcranial magnetic stimulation, or TMS, to create a pulsed, MRI-strength magnetic field that induces electrical currents designed to stimulate specific areas of the brain associated with mood. The company designed the NeuroStar Advance Therapy as a non-invasive therapeutic alternative to treat patients who suffer from MDD and to address the existing treatment options. The company operates in two segments: medical devices and clinic services.
Perspective Therapeutics Inc is a radiopharmaceutical development company that is pioneering advanced treatment applications for cancers throughout the body. The Company has a proprietary technology that utilizes the alpha-emitting isotope Lead-212 (212Pb) to deliver powerful radiation specifically to cancer cells via specialized targeting moieties.